Navigation Links
CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
Date:10/24/2007

- Initial clinical trial results suggesting safety and clinical activity of CR011-vcMMAE reported at the AACR-NCI-EORTC International Conference -

BRANFORD, Conn., Oct. 24 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced that the first Phase I clinical trial results on CR011- vcMMAE, an antibody-drug conjugate (ADC) being developed for the treatment of metastatic melanoma, were presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA. To date, 25 patients with unresectable Stage III or IV malignant melanoma have been treated with CR011-vcMMAE in the Phase I dose-escalation portion of the trial.

Results from the ongoing trial suggest the CR011-vcMMAE is well-tolerated at doses up through 1.88 mg/kg with no dose-limiting toxicities noted. Dose- escalation continues with patients currently being enrolled into the 2.63 mg/kg cohort. Of the 25 patients treated with doses ranging from 0.03 mg/kg to 1.88 mg/kg, six patients achieved stable disease lasting up to 11 cycles, and four of the six patients demonstrated tumor shrinkage of up to 20%. Reversible neutropenia was the only drug-related Grade 3 or 4 adverse event, and appears to be dose-dependent. Evaluation of the pharmacokinetic results also suggest that CR011-vcMMAE can be given safely to achieve human plasma concentrations in the anticipated range of activity based on data from in vivo xenograft animal models.

Upon establishing the maximum tolerated dose (MTD), the trial is expected to expand directly into a Phase II study to further assess the activity of CR011-vcMMAE in up to 32 patients wit
'/>"/>

SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
(Date:12/17/2014)... -- Los beneficios y ganancias están por ... gasto en investigación y desarrollo   En ... septiembre de 2014) ZEISS aumentó sus ingresos en un ... anterior: 4.190 millones de euros) a pesar de los ... un 14 por ciento, a 360 millones de euros. ...
(Date:12/17/2014)... 17, 2014 With advancements in neurological ... market is seeing new growth, according to Kalorama ... account for the majority of market volume, newer ... images, which are creating opportunities for more sophisticated applications. ... growing at a rate of 4%, with world ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3
... Stereotaxis, Inc. (Nasdaq: STXS ) announced today that ... September 30, 2010, on Monday, November 1, 2010 ... a conference call and webcast on Monday, November 1, ... Company,s third quarter results and corporate developments. The ...
... Oct. 25 Accuray Incorporated (Nasdaq: ARAY ), ... that it will report results for its first quarter of ... 2010 after the market closes. A conference call ... p.m. ET and will be hosted by Euan S. Thomson, ...
Cached Medicine Technology:Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call 2Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call 3Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2011 2
(Date:12/19/2014)... Sweetdressy.com , a leading wedding dress manufacturer for the ... prom dresses for ladies worldwide. The prom dresses from ... can buy these dresses at the website of Sweetdressy.com ... and delicate craftsmanship, and most of them are priced ... costs are available for all of their dresses. All ...
(Date:12/19/2014)... FL (PRWEB) December 19, 2014 ... Revitalizing Bedsheets are now available. Celliant, the world’s ... both sheets and pillowcases. , There are a ... proven additional circulation, increased oxygenation and balanced body ... faster healing and pain relief; enhanced athletic performance; ...
(Date:12/19/2014)... Silver Dollar City is picking ... for the first time ever, Silver Dollar City has a ... Records 2015, listing the park’s wood coaster Outlaw Run as ... awards announced this week, Silver Dollar City is named in ... US,” USA Today’s 10Best awards for “Best Public Lights Display,” ...
(Date:12/19/2014)... 2014 Eufaula, Oklahoma, located just 9 ... the state’s largest lake with more than 600 miles ... to a little more than 3,000 residents, hosted its ... the 6th of December. , Featuring Santa, Christmas lights ... Eufaula on Main Street. Narconon Arrowhead’s parade float ...
(Date:12/19/2014)... 20, 2014 An evening dress is perfect ... lady’s closet. Discount-Dress.com, a distinguished dresses retailer, has unveiled its ... dresses in this great shopping platform. Customers can ... staff's hard work, Discount-Dress.com has been accepted and praised by ... and easier shopping stage for clients. In order to expand ...
Breaking Medicine News(10 mins):Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2
... to rid the brain of the amyloid buildup that plagues ... the method outlined in a paper published online August 12 ... Center show how the bodys natural way of ridding the ... disease. Then the team demonstrated an experimental method in mice ...
... 2007 UT Southwestern Medical Center researchers have discovered ... the human cardiovascular system, including lowering the elevated heart ... ,We have found that cocaines effects on the ... a drug called dexmedetomidine, which is currently approved by ...
... Food and Drug Administration (FDA) Nanotechnology Task Force is ... effort to tackle the new scientific and regulatory challenges ... clear and candid in acknowledging the pervasive potential of ... pharmaceuticals and devices to cosmetics and food supplements— and ...
... drug that stimulates the growth of infection-fighting white blood ... a chemotherapy-related complication characterized by fever and low white ... by researchers from the University of Rochester School of ... Center. , "Chemotherapy drugs target cancer cells, but ...
... scientists said Monday that they have further evidence to suggest ... would make a promising target for new drugs to ... first identified the enzyme, protein kinase G (PknG), as a ... time, they said that the protein is the secret weapon ...
... created from an egg matured in a laboratory, frozen, thawed ... a medical conference on Monday. ,The baby ... disease, and three other women in the 20-person trial group ... ,Doctors already collect and store eggs from women who face ...
Cached Medicine News:Health News:Draining away brain's toxic protein to stop Alzheimer's 2Health News:Draining away brain's toxic protein to stop Alzheimer's 3Health News:New treatment effective in counteracting cocaine-induced symptoms 2Health News:White Blood Cell Booster May Help Cancer Patients Avoid Deadly Complications 2Health News:Structure of TB Enzyme Points the Way to New Drugs: Study 2Health News:Infertility Breakthrough With First Birth from Lab-matured Egg 2Health News:Infertility Breakthrough With First Birth from Lab-matured Egg 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: